Market research
TRIL.TO Trillium Therapeutics Inc
TO CAD Healthcare
Latest close
As of 29 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 18.5
- Dividend yield
- 0.0%
- Beta
- 1.9
Profile
Instrument facts
- Exchange
- TO
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA89620X5064
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 18.5
- Dividend yield
- 0.0%
- Beta
- 1.9
About
About Trillium Therapeutics Inc
As of November 17, 2021, Trillium Therapeutics Inc. was acquired by Pfizer Inc. Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Cambridge, Massachusetts.
Research context
Trillium Therapeutics Inc appears in PyInvesting’s Toronto Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the TRIL.TO discussion.
5 years, 6 months ago
Trillium Therapeutics Inc is currently in a long term downtrend where the price is trading 27.1% below its 200 day moving average.
From a valuation standpoint, the stock is 508.9% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 6213.3.
Trillium Therapeutics Inc's total revenue rose by 5246.8% to $33K since the same quarter in the previous year.
Its net income has increased by 694.1% to $114M since the same quarter in the previous year.
Finally, its free cash flow fell by 11.3% to $-5M since the same quarter in the previous year.
Based on the above factors, Trillium Therapeutics Inc gets an overall score of 2/5.